Revolution Medicines 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mark Goldsmith

최고 경영자

US$10.4m

총 보상

CEO 급여 비율	6.1%
CEO 임기	10yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	6.5yrs
이사회 평균 재임 기간	7.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Mark Goldsmith 의 보수는 Revolution Medicines 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$567m
Jun 30 2024	n/a	n/a	-US$519m
Mar 31 2024	n/a	n/a	-US$484m
Dec 31 2023	US$10m	US$631k	-US$436m
Sep 30 2023	n/a	n/a	-US$331m
Jun 30 2023	n/a	n/a	-US$296m
Mar 31 2023	n/a	n/a	-US$259m
Dec 31 2022	US$7m	US$607k	-US$249m
Sep 30 2022	n/a	n/a	-US$245m
Jun 30 2022	n/a	n/a	-US$224m
Mar 31 2022	n/a	n/a	-US$208m
Dec 31 2021	US$8m	US$581k	-US$187m
Sep 30 2021	n/a	n/a	-US$169m
Jun 30 2021	n/a	n/a	-US$143m
Mar 31 2021	n/a	n/a	-US$126m
Dec 31 2020	US$2m	US$554k	-US$110m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$85m
Mar 31 2020	n/a	n/a	-US$71m
Dec 31 2019	US$5m	US$504k	-US$62m
Sep 30 2019	n/a	n/a	-US$57m
Dec 31 2018	US$1m	US$490k	-US$49m

보상 대 시장: Mark 의 총 보상 ($USD 10.41M )은 German 시장( $USD 3.59M ).

보상과 수익: 회사가 수익성이 없는 동안 Mark 의 보상이 증가했습니다.

CEO

Mark Goldsmith (62 yo)

10yrs

테뉴어

US$10,411,247

보상

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Goldsmith	CEO, President & Chairman	10yrs	US$10.41m	0.39% € 35.7m
Jack Anders	Chief Financial Officer	6.3yrs	US$3.05m	0.029% € 2.7m
Margaret Horn	Chief Operating Officer	6.1yrs	US$4.39m	0.033% € 3.0m
Stephen Kelsey	President of Research & Development	7.7yrs	US$4.39m	0.11% € 9.7m
Xiaolin Wang	Executive Vice President of Development	6.7yrs	US$3.23m	0.015% € 1.4m
Martin Burke	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kevan Shokat	Academic Co-Founder & Member of Scientific Advisory Board	7.9yrs	데이터 없음	데이터 없음
Walter Reiher	Chief Information Officer	no data	데이터 없음	데이터 없음
Jan Smith	Chief Scientific Officer	1.3yrs	데이터 없음	데이터 없음
Erin Graves	Senior Director of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Jeff Cislini	Senior VP	2.2yrs	데이터 없음	0.0017% € 156.8k

6.5yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 42Z 의 관리팀은 노련하고 경험 (평균 재직 기간 6.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Goldsmith	CEO, President & Chairman	10yrs	US$10.41m	0.39% € 35.7m
Martin Burke	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
Kevan Shokat	Academic Co-Founder & Member of Scientific Advisory Board	7.9yrs	데이터 없음	데이터 없음
Julian Adams	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	데이터 없음	데이터 없음
Alexis Borisy	Lead Independent Director	10yrs	US$510.63k	1.39% € 127.1m
Eric Gordon	Senior Advisor & Member of Scientific Advisory Board	8.4yrs	데이터 없음	데이터 없음
John Kuriyan	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	데이터 없음	데이터 없음
Lorence Kim	Independent Director	2.3yrs	US$489.99k	0.036% € 3.3m
Thilo Schroeder	Independent Director	6.7yrs	데이터 없음	데이터 없음
Elizabeth Anderson	Independent Director	9.7yrs	US$483.78k	0.025% € 2.3m
Trever Bivona	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	데이터 없음	데이터 없음

7.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 42Z 의 이사회는 경험(평균 재직 기간 7.9 년)으로 간주됩니다.

Revolution Medicines 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

Revolution Medicines, Inc. Announces Executives Appointment

Revolution Medicines, Inc. Announces Executive Changes

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Recent updates

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Now 22% undervalued

Now 20% undervalued

New major risk - Revenue size

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024

Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million.

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024

Full year 2023 earnings released: US$3.86 loss per share (vs US$3.09 loss in FY 2022)

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Shareholder dilution

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022)

Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

New major risk - Revenue and earnings growth

New major risk - Share price stability

Revolution Medicines, Inc. Provides Pipeline Updates

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.82 loss in 2Q 2022)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023

Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index

First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.78 loss in 1Q 2022)

Revolution Medicines, Inc. Announces Executives Appointment

Full year 2022 earnings released: US$3.09 loss per share (vs US$2.57 loss in FY 2021)

Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552

Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. Updates Earnings Guidance for 2022

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.72 loss in 3Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Revolution Medicines, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.60 loss in 2Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Year 2022

Revolution Medicines, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Revolution Medicines, Inc. Elects Sushil Patel to its Board of Directors

Revolution Medicines, Inc. Appoints Sushil Patel, Ph.D. as Director

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.53 loss in 1Q 2021)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Revolution Medicines, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

Third quarter 2021 earnings released: US$0.72 loss per share (vs US$0.42 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2020)

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2021

Revolution Medicines, Inc. Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Independent Director Peter Svennilson has left the company

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2021

First quarter 2021 earnings released: US$0.53 loss per share (vs US$0.74 loss in 1Q 2020)

Full year 2020 earnings released: US$2.01 loss per share (vs US$22.33 loss in FY 2019)

Revenue misses expectations

New 90-day high: €37.80